This molecule, efficient to inhibit both lymphangiogenesis and hemangiogenesis (80), is considered as a valuable tool to control metastatic CRC growth since several studies reported its moderate toxicity without observing the increased metastatic dissemination encountered in response to the anti-VEGF antibody bevacizumab (30). The gene discussed is VEGFA; the disease is colorectal carcinoma.